Present Serious, Not Common, Risks First, FDA Tells Watson In Letter On Gelnique
This article was originally published in The Pink Sheet Daily
Executive Summary
"Restroom stall cling" for the urinary incontinence drug used at medical meeting gets notice of violation letter from DDMAC.
You may also be interested in...
Don’t Count Those Pennies Just Yet: Watson Cited For Claiming Cost Savings From Sodium Ferric Gluconate
FDA’s Office of Prescription Drug Promotion objected to economic claims that the product could reduce ESA use in part because they were based on a subset of the approved population.
Auxilium Widened Claims For Dupuytren's Contracture Drug Xiaflex, FDA Says
Auxilium Pharmaceuticals' eagerness to draw attention to its new therapy for Dupuytren's disease, rather than any competitive pressure, has resulted in a speedy FDA "untitled" letter for a Xiaflex promotion
Short Attention Span? Shire Cited Again For Out-Of-Bounds ADHD Promotion
FDA says that Intuniv patient materials claimed it treats such non-ADHD behavioral problems as temper outbursts.